Literature DB >> 21446746

The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts.

John M Louis1, Ying Zhang, Jane M Sayer, Yuan-Fang Wang, Robert W Harrison, Irene T Weber.   

Abstract

The mature HIV-1 protease (PR) bearing the L76V drug resistance mutation (PR(L76V)) is significantly less stable, with a >7-fold higher dimer dissociation constant (K(d)) of 71 ± 24 nM and twice the sensitivity to urea denaturation (UC(50) = 0.85 M) relative to those of PR. Differential scanning calorimetry showed decreases in T(m) of 12 °C for PR(L76V) in the absence of inhibitors and 5-7 °C in the presence of inhibitors darunavir (DRV), saquinavir (SQV), and lopinavir (LPV), relative to that of PR. Isothermal titration calorimetry gave a ligand dissociation constant of 0.8 nM for DRV, ∼160-fold higher than that of PR, consistent with DRV resistance. Crystal structures of PR(L76V) in complexes with DRV and SQV were determined at resolutions of 1.45-1.46 Å. Compared to the corresponding PR complexes, the mutated Val76 lacks hydrophobic interactions with Asp30, Lys45, Ile47, and Thr74 and exhibits closer interactions with Val32 and Val56. The bound DRV lacks one hydrogen bond with the main chain of Asp30 in PR(L76V) relative to PR, possibly accounting for the resistance to DRV. SQV shows slightly improved polar interactions with PR(L76V) compared to those with PR. Although the L76V mutation significantly slows the N-terminal autoprocessing of the precursor TFR-PR(L76V) to give rise to the mature PR(L76V), the coselected M46I mutation counteracts the effect by enhancing this rate but renders the TFR-PR(M46I/L76V) precursor less responsive to inhibition by 6 μM LPV while preserving inhibition by SQV and DRV. The correlation of lowered stability, higher K(d), and impaired autoprocessing with reduced internal hydrophobic contacts suggests a novel molecular mechanism for drug resistance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21446746      PMCID: PMC3101314          DOI: 10.1021/bi200033z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  38 in total

1.  Characterization of two hydrophobic methyl clusters in HIV-1 protease by NMR spin relaxation in solution.

Authors:  R Ishima; J M Louis; D A Torchia
Journal:  J Mol Biol       Date:  2001-01-19       Impact factor: 5.469

2.  Autoprocessing of HIV-1 protease is tightly coupled to protein folding.

Authors:  J M Louis; G M Clore; A M Gronenborn
Journal:  Nat Struct Biol       Date:  1999-09

3.  Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism.

Authors:  J M Louis; E M Wondrak; A R Kimmel; P T Wingfield; N T Nashed
Journal:  J Biol Chem       Date:  1999-08-13       Impact factor: 5.157

4.  Structural and kinetic analysis of drug resistant mutants of HIV-1 protease.

Authors:  B Mahalingam; J M Louis; C C Reed; J M Adomat; J Krouse; Y F Wang; R W Harrison; I T Weber
Journal:  Eur J Biochem       Date:  1999-07

5.  Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.

Authors:  M J Todd; I Luque; A Velázquez-Campoy; E Freire
Journal:  Biochemistry       Date:  2000-10-03       Impact factor: 3.162

Review 6.  HIV-1 protease: maturation, enzyme specificity, and drug resistance.

Authors:  J M Louis; I T Weber; J Tözsér; G M Clore; A M Gronenborn
Journal:  Adv Pharmacol       Date:  2000

Review 7.  HIV-1 protease: mechanism and drug discovery.

Authors:  Ashraf Brik; Chi-Huey Wong
Journal:  Org Biomol Chem       Date:  2003-01-07       Impact factor: 3.876

8.  Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.

Authors:  Bhuvaneshwari Mahalingam; Yuan-Fang Wang; Peter I Boross; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  Eur J Biochem       Date:  2004-04

9.  Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.

Authors:  Nancy M King; Moses Prabu-Jeyabalan; Ellen A Nalivaika; Piet Wigerinck; Marie-Pierre de Béthune; Celia A Schiffer
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

10.  High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.

Authors:  Yunfeng Tie; Peter I Boross; Yuan-Fang Wang; Laquasha Gaddis; Azhar K Hussain; Sofiya Leshchenko; Arun K Ghosh; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2004-04-23       Impact factor: 5.469

View more
  13 in total

1.  HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Annie Aniana; Jane M Sayer; John M Louis; Irene T Weber
Journal:  Biochemistry       Date:  2012-03-20       Impact factor: 3.162

2.  Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Authors:  Yu-Chung E Chang; XiaXia Yu; Ying Zhang; Yunfeng Tie; Yuan-Fang Wang; Sofiya Yashchuk; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

Review 3.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

4.  Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.

Authors:  Daniel W Kneller; Johnson Agniswamy; Robert W Harrison; Irene T Weber
Journal:  FEBS J       Date:  2020-01-23       Impact factor: 5.542

5.  Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1.

Authors:  Vici Varghese; Yumi Mitsuya; W Jeffrey Fessel; Tommy F Liu; George L Melikian; David A Katzenstein; Celia A Schiffer; Susan P Holmes; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

6.  Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.

Authors:  Yunfeng Tie; Yuan-Fang Wang; Peter I Boross; Ting-Yi Chiu; Arun K Ghosh; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  Protein Sci       Date:  2012-01-24       Impact factor: 6.725

7.  Characterizing early drug resistance-related events using geometric ensembles from HIV protease dynamics.

Authors:  Olivier Sheik Amamuddy; Nigel T Bishop; Özlem Tastan Bishop
Journal:  Sci Rep       Date:  2018-12-18       Impact factor: 4.379

8.  Dimer Interface Organization is a Main Determinant of Intermonomeric Interactions and Correlates with Evolutionary Relationships of Retroviral and Retroviral-Like Ddi1 and Ddi2 Proteases.

Authors:  János András Mótyán; Márió Miczi; József Tőzsér
Journal:  Int J Mol Sci       Date:  2020-02-17       Impact factor: 5.923

9.  Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease.

Authors:  Debra A Ragland; Ellen A Nalivaika; Madhavi N L Nalam; Kristina L Prachanronarong; Hong Cao; Rajintha M Bandaranayake; Yufeng Cai; Nese Kurt-Yilmaz; Celia A Schiffer
Journal:  J Am Chem Soc       Date:  2014-08-18       Impact factor: 15.419

10.  Drug Resistance Mutation L76V Alters Nonpolar Interactions at the Flap-Core Interface of HIV-1 Protease.

Authors:  Andres Wong-Sam; Yuan-Fang Wang; Ying Zhang; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  ACS Omega       Date:  2018-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.